Strong YoY Growth, Flat Quarter—The Market Smells the Sequential Problem
Reported numbers matched call claims exactly: ₹1,477 Cr revenue (+22% YoY), ₹180 Cr PAT (+60% YoY). Yet the stock fell 2.91% on day 1 and 4.81% by day 3. The reason is buried in the 'strongest quarter ever' framing—quarter-on-quarter, revenue grew just 0.4% and profit declined 10.7%.
+22%
₹1,477 Cr; exceeded by exact call claim
+0.4%
Flat quarter despite 'strongest ever' framing
+59.8%
₹180 Cr; call rounds to +60%
-10.7%
Profit declined despite YoY enthusiasm
22.9%
+256 bps YoY; driven by complex generics mix (39%→50%)
On the earnings screen, Q1 FY-2027 looked like a blowout. Revenue ₹1,477 Cr and PAT ₹180 Cr both hit their call forecasts exactly. Margins expanded 256 basis points year-on-year. Management called it the 'strongest quarter ever.' And yet, on day 1 post-announcement, the stock fell 2.91%. By day 3, it was down 4.81%. The market heard what management didn't lead with: quarter-on-quarter, revenue grew just 0.4% and PAT declined 10.7%. That gap between the YoY narrative and the sequential reality is the story of this quarter.
Claims vs. what holds up
Revenue grew 22% to ₹1,477 Cr
Delivered ₹1,476.8 Cr, +22.0% YoY confirmed
Supported
PAT grew 60% to ₹180 Cr
Delivered ₹180 Cr, +59.8% YoY (call rounds to 60%)
Supported
Gross margin expanded 74 bps YoY
Consistent with EBITDA margin +256 bps YoY; no conflict
Supported
Complex generics grew to 50% of finished dosages from 39% YoY
Confirmed; mix shift driving 256 bps EBITDA expansion
Supported
Strongest Q1 ever
True on YoY (+22% revenue, +60% PAT); false on QoQ (+0.4% revenue, -10.7% PAT)
Overstated (YoY bias)
Europe growth strong year-on-year
Confirmed YoY; sequential softness intentional due to pricing/cost pressures
Supported but qualified
Peptide CDMO $50M revenue by mid-FY29 with 30%+ EBITDA
Quantified and feasible; Q1 showed CHF 5M (~₹40 Cr run-rate) with ₹-12 Cr EBITDA loss
Credible long-term; lumpy near-term
What changed on this call
Peptide CDMO guidance hardened materially. Prior guidance (FY26 call): 'PAT positive on annual basis FY27.' This call: '$50 million revenue run-rate with 30%+ EBITDA margins by mid-FY29, anchored by 3 customer wins at $10M+ each.' The target is now quantified and time-bounded—a material upgrade in specificity. Complex generics mix jumped to 50% of finished dosages (from 39% YoY), now the margin engine driving 256 bps EBITDA expansion. Gagillapur facility status unchanged—7 of 8 facilities have clean regulatory inspection reports, but the Gagillapur facility remains pending FDA clearance with 9 applications queued behind it. Capex guidance reaffirmed at ₹600 Cr for FY27; Genome Valley facility investment completed, next phase is digitalization and modular growth at existing facilities.
The bull-bear ledger
22% YoY revenue growth (₹1,477 Cr) anchored by strong NA demand and formulations
60% YoY PAT growth (₹180 Cr) with EBITDA margin +256 bps—quality expansion
ROCE 18% (up from 17.6% Q4) and expanding on back of margin and capital efficiency
Net debt only ₹1,012 Cr (~0.07x EBITDA)—essentially debt-free and self-funding capex
Operating cash flow ₹387 Cr in Q1; capex ₹89 Cr—free cash generation ₹298 Cr
Peptide CDMO milestone hardened to $50M by mid-FY29; 3 new customer wins initiated Q1
Sequential revenue +0.4%, PAT -10.7%—momentum loss masked by YoY framing
Gagillapur FDA clearance still pending (binary event); 9 applications queued behind it
Peptide CDMO Q1 showed ₹-12 Cr EBITDA loss despite CHF 5M (~₹40 Cr run-rate) revenue
Raw material inflation 'quite high'; Europe supply intentionally held due to pricing power constraints
Genome Valley and peptide GLS facility utilization 'very low'; crossing 50% only by year-end
Capex-heavy FY27 (₹600 Cr); ROCE expansion benefits deferred into FY28+
Risks, ranked by severity
Gagillapur FDA clearance still pending
HighBinary event. Remediation claimed on-track (330+ audits in 2 years, no critical observations); yet clearance timing unknown. 9 applications—ADHD, sodium oxybate (sole first-to-file), oncology—queued behind it. Delay compounds sequential weakness and undermines FY27 growth guidance.
Raw material inflation + pricing power constraint
HighManagement acknowledged RM costs 'quite high.' Europe supply intentionally held due to inability to pass pricing on legacy generic 5 business. If inflation persists, EBITDA margin guidance of 22–23% is at risk. Gross margin expansion from mix may not fully offset.
Sequential revenue plateau (revenue +0.4%, PAT -10.7% QoQ)
HighFY27 growth guidance deferred ('growth will continue'; specific number withheld). If Q2 is also flat or negative, credibility of the 22% YoY growth continuing into FY27 deteriorates sharply.
Peptide CDMO quarterly lumpiness and project dependency
MediumQ1 showed ₹-12 Cr EBITDA loss on CHF 5M revenue. Long cycle times and project-to-product mix variation cause volatility. PAT positive target for FY27 assumes strong H2; risk if projects slip into FY28.
New facility capacity utilization drag
MediumGenome Valley (complex generics) and GLS (peptide) both 'very low' utilization; expected to cross 50% only by year-end. Capex-heavy (₹511 Cr remaining in FY27) with ROCE expansion deferred.
Litigation-dependent product launch timelines
MediumDyanavel and Adzenys (ADHD controlled substances) timelines management cannot disclose due to IP litigation. 9 of 18 pending US approvals are litigation-based. No visibility on commercialization pace.
How the street is positioned
The post-result stock move tells the story better than any earnings call. Granules delivered ₹1,477 Cr revenue and ₹180 Cr PAT—exactly as guided. Yet the stock fell 2.91% on day 1 post-announcement and extended losses to 4.81% by day 3. At ₹833.55, it now trades 8.39% below its all-time high of ₹909.9, though still up 57.3% from its 52-week low of ₹529.85. RSI at 42.4 is neutral—not yet oversold—suggesting scope for further weakness if momentum doesn't recover. However, FII ownership rose 1.76 percentage points QoQ to 15.31%, indicating foreign institutions are nibbling on the dip. This is a vote of confidence in the long-term strategy (peptide CDMO, oncology pipeline) despite near-term headwinds. The market's read is clear: strong YoY growth is real, but sequential stasis and Gagillapur uncertainty make near-term visibility weak.
1 · Q2 FY27: Gagillapur FDA inspection and clearance decision
The lynchpin. Clearance would unlock 9 applications (ADHD, sodium oxybate, oncology formulations) for launch. Delay compounds sequential weakness. Management claims readiness 'every single day'; betting markets should front-load this catalyst.
2 · Q2 sequential revenue growth—the momentum test
Q1's +0.4% QoQ is not convincing. If Q2 revenue is >2–3% QoQ, momentum is back and 'continued FY27 growth' is credible. If flat again, pricing pressure is structural and Gagillapur becomes make-or-break.
3 · H2 FY27: Peptide CDMO revenue and profitability ramp
PAT positive target for FY27 assumes strong H2 after Q1's ₹-12 Cr EBITDA loss. Watch for sequential peptide revenue uplift and EBITDA improvement. H2 has historically been stronger than H1.
4 · FY28 (starts Apr 2027): First oncology self-developed product launch
Pipeline validation. 9–13 oncology products in development; first commercial launch signals execution risk and addressable market traction. Long-term value driver but not near-term earnings impact.
Granules India delivered a fundamentally sound quarter: margins expanding, cash generation strong, and long-term strategy credible (peptide CDMO $50M target, oncology pipeline, complex generics mix). But the sequential momentum is unmistakably flat, and the 'strongest quarter ever' framing was an optical choice—emphasizing YoY while downplaying QoQ weakness (+0.4% revenue, -10.7% PAT). The market smelled this correctly and sold off 4.8% by day 3.
Rating: Hold. The bull case exists (Gagillapur clearance, peptide H2 ramp, FY28 oncology launches), but timing is uncertain and near-term momentum is at risk from RM inflation and pricing constraints. A holder should wait for either (a) Gagillapur clearance announcement, or (b) Q2 sequential revenue growth >2–3%. Until then, the stock is priced fairly at an 8.39% discount to its all-time high.
The number to track from here: Q2 sequential revenue growth. If flat again, Gagillapur is make-or-break.
Informational and educational content only. Not investment advice.